全文获取类型
收费全文 | 373030篇 |
免费 | 27249篇 |
国内免费 | 9045篇 |
专业分类
耳鼻咽喉 | 4788篇 |
儿科学 | 10473篇 |
妇产科学 | 6757篇 |
基础医学 | 31795篇 |
口腔科学 | 15080篇 |
临床医学 | 39916篇 |
内科学 | 44911篇 |
皮肤病学 | 4733篇 |
神经病学 | 19902篇 |
特种医学 | 9704篇 |
外国民族医学 | 48篇 |
外科学 | 45888篇 |
综合类 | 56019篇 |
现状与发展 | 17篇 |
一般理论 | 29篇 |
预防医学 | 35197篇 |
眼科学 | 5328篇 |
药学 | 31652篇 |
389篇 | |
中国医学 | 31491篇 |
肿瘤学 | 15207篇 |
出版年
2023年 | 5758篇 |
2022年 | 8419篇 |
2021年 | 13804篇 |
2020年 | 13661篇 |
2019年 | 19391篇 |
2018年 | 17068篇 |
2017年 | 14076篇 |
2016年 | 11552篇 |
2015年 | 11070篇 |
2014年 | 22161篇 |
2013年 | 24396篇 |
2012年 | 20073篇 |
2011年 | 21921篇 |
2010年 | 17810篇 |
2009年 | 16415篇 |
2008年 | 15940篇 |
2007年 | 16533篇 |
2006年 | 14471篇 |
2005年 | 12827篇 |
2004年 | 10538篇 |
2003年 | 9260篇 |
2002年 | 7335篇 |
2001年 | 6572篇 |
2000年 | 5428篇 |
1999年 | 4691篇 |
1998年 | 3626篇 |
1997年 | 3457篇 |
1996年 | 3034篇 |
1995年 | 3003篇 |
1994年 | 2925篇 |
1993年 | 2294篇 |
1992年 | 2324篇 |
1991年 | 1996篇 |
1990年 | 1753篇 |
1989年 | 1575篇 |
1988年 | 1459篇 |
1987年 | 1238篇 |
1985年 | 3919篇 |
1984年 | 4897篇 |
1983年 | 3442篇 |
1982年 | 3903篇 |
1981年 | 3630篇 |
1980年 | 3233篇 |
1979年 | 2987篇 |
1978年 | 2618篇 |
1977年 | 1961篇 |
1976年 | 2200篇 |
1975年 | 1665篇 |
1974年 | 1438篇 |
1973年 | 1293篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
61.
目的 建立蒙药绿松石的质量标准。方法 收集不同产地绿松石,共10批。观察绿松石样品和粉末的性状并进行理化鉴别;按2020年版《中国药典》(四部)通则方法测定绿松石样品中水分、浸出物含量;采用原子吸收光谱法测定绿松石样品铜元素含量。结果 绿松石为不规则、周围带有黑石的块状物,表面蓝绿色,体重,质硬脆,难砸碎,断面呈贝壳状,蜡样光泽,粉末呈灰绿色,无臭,味淡;理化鉴别结果显示,呈铜盐反应;10批次样品中水分含量为0.41%-3.94%(SD=1.37%),浸出物含量为0.21%-0.81%(SD=0.21%),铜元素含量为3.03%-4.63%(SD=0.63%)。结论 初步拟定绿松石中水分含量不得超多5.0%、浸出物含量不得低于0.10%,铜元素含量应为2.60%-4.84%,制定的标准可用于蒙药材绿松石的质量控制。 相似文献
62.
《European journal of surgical oncology》2022,48(3):500-507
IntroductionThe aim of this study was to compare long-term patient reported outcomes (PROs) in patients with locally advanced extremity soft tissue sarcoma (eSTS) after isolated limb perfusion followed by resection (IR), compared to extended resection (ER), primary amputation (A) or secondary amputation after IR (IR-A).MethodsPatients were selected from the respondents of a multi-institutional cross-sectional cohort survivorship study (SURVSARC) conducted among sarcoma survivors registered in the Netherlands Cancer Registry (NCR), 2–10 years after diagnosis. Used PROs were the EORTC QLQ-C30, the Cancer worry scale (CWS), the Hospital Anxiety and Depression Scale (HADS), and the Toronto Extremity Salvage Score (TESS).ResultsWe identified 97 eSTS survivors: IR = 20, ER = 49, A = 20, IR-A = 8. While there were no differences in PROs between IR and ER, results showed better functioning and functionality in both groups versus the amputation groups. The amputation groups scored significantly lower on physical functioning (A = 62.7, IR-A = 65.7 versus IR = 78.0, ER = 82.7, p = 0.001) and role functioning (A = 67.5, IR-A = 52.8 versus IR = 79.2, ER = 80.6, p = 0.039), both EORTC QLQ-C30 scales. Also for the TESS, the scores were significantly lower for the amputation groups compared to the limb sparing groups (upper extremity p = 0.007 with A = 68.9, IR-A = 71.6 versus IR = 93.3, ER = 91.1; lower extremity p < 0.001 with A = 72.2, IR-A50.9 versus IR = 84.5 and ER = 85.5). There were no significant differences between the groups on cancer worry, anxiety and depression.ConclusionHRQoL in eSTS survivors treated with IR or ER is equal; for maintenance of physical functioning and functionality IR and ER outperform an amputation. 相似文献
63.
Nicolas Penel Sylvie Bonvalot Marie-Cécile Le Deley Antoine Italiano Camille Tlemsani Diane Pannier Clémence Leguillette Jean-Emmanuel Kurtz Maud Toulmonde Julien Thery Daniel Orbach Pascale Dubray-Longeras Benjamin Verret François Bertucci Cécile Guillemet Lucie Laroche Armelle Dufresne Jean-Yves Blay Axel Le Cesne 《International journal of cancer. Journal international du cancer》2023,153(2):407-416
The aim of this study is to evaluate the prevalence, determinants and prognostic value of pain at diagnosis in patients with desmoid-type fibromatosis (DF). We selected patients from the ALTITUDES cohort (NCT02867033), managed by surgery, active surveillance or systemic treatments, with pain assessment at diagnosis. Patients were invited to fill QLQ-C30 questionnaire and Hospital Anxiety Depression Scale. Determinants were identified using logistic models. Prognostic value on event-free survival (EFS) was evaluated using the Cox model. Overall, 382 patients were included in the current study (median age: 40.2 years; 117 men). The prevalence of pain was 36%, without significant difference according to first-line treatment (P = .18). In the multivariate analysis, pain was significantly associated with tumor size >50 mm (P = .013) and tumor site (P < .001); pain was more frequent in the neck and shoulder locations (odds ratio: 3.05 [1.27-7.29]). Pain at baseline was significantly associated with poor quality of life (P < .001), depression (P = .02), lower performance status (P = .03) and functional impairment (P = .001); we also observed a nonsignificant association with anxiety (P = .10). In the univariate analysis, baseline pain was associated with poor EFS; the 3-year EFS was 54% in patients with pain compared to 72% in those without pain. After adjustment for sex, age, size and line of treatment, pain was still associated with poor EFS (hazard ratio: 1.82 [1.23-2.68], P = .003). One third of recently diagnosed patients with DF experienced pain, especially those with larger tumors and neck/shoulder locations. Pain was associated with unfavorable EFS after adjustment for the confounders. 相似文献
64.
65.
66.
67.
68.
PurposeGlioblastoma multiforme (GBM) is the most common malignant brain tumor. Moreover, GBM recurs in nearly all patients. Although a standard STUPP protocol has been widely used for newly diagnosed GBM, no standard regimen has been established for recurrent patients. Here we evaluated the clinical value of recurrent GBM reoperation by comparing overall survival and quality of life (QoL) in patients with recurrent GBM undergoing repeat surgery or conservative treatment.MethodsThis was a prospective study of 165 patients with GBM receiving first operations for their disease between 2011 and 2013 at two tertiary neurosurgery centers in Poland. Thirty-five eligible patients were re-operated for recurrence (the study group), and 35 patients were selected as the control group using propensity score matching. A model was created to determine advantageous prognostic factors for longer survival of patients qualifying for reoperation using stepwise linear regression.ResultsThe mean overall survival of patients undergoing repeat surgery was 528 days compared to 297 days in patients who did not undergo repeat surgery. Reoperation did not result in a significant deterioration in performance status as measured by the Karnofsky Performance Scale. Older age, the presence of symptoms of increased intracranial pressure, and a shorter period between initial operation and reoperation were independent predictors of a worse outcome.ConclusionIn selected patients, reoperation for recurrent GBM prolongs survival with no significant deteriorations in performance status. 相似文献
69.
70.